Sign in
Not yet taking people in United StatesPhase 4

Daridorexant for sleep problems in smokers who stop smoking

Tests daridorexant against placebo for insomnia in smokers during quitting.

Key facts

Who runs it
Legacy Health System
Where
Portland, United StatesSee the site
Trial code
Registry title
Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking
Status
Not yet recruiting
Phase
Phase 4
People taking part
44 people, planned
Started
10 Feb 2026
Expected to end
30 Sept 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Daridorexant 50 mg
  • Placebo
Record updated
9 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult cigarette smokers who are willing to try to cut down or stop smoking for 3 weeks. It tests daridorexant, a sleep medicine, against a placebo (dummy pill).

Age
18-55 years
Sex
All sexes
Disease stage
Smoking more than 10 cigarettes a day, for 1 year or longer.
Earlier treatment
People cannot join if they currently use quit-smoking medicines or therapy (nicotine patch or gum, buproprion, varenicline, cognitive behavioral therapy for smoking). People cannot join if they currently take sleep medicines, ADHD stimulants or anti-seizure drugs.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Sleep apnea, narcolepsy or another diagnosed sleep disorder
  • Substance use disorder other than nicotine, or a serious neurological or psychiatric disorder
  • Thyroid problems or COPD
  • BMI of 33 or higher

The registry criteria, word for word

Show all 25 criteriaShow less

Other criteria

  • INCLUSION
  • Adult participants who are cigarette smokers, 18-55 years of age
  • Smokers: greater than 10 cigarettes/day
  • Smoking for 1 year or longer
  • Willingness to try to reduce or stay abstinent from cigarettes, smoking cessation aides (including nicotine gum or patches), smokeless tobacco, or electronic cigarettes for 3 weeks during the study
  • Willingness to monitor sleep at home with an external device and maintain a simple sleep and smoking diary for 3 weeks
  • Willingness to take a 5-min, mobile-based test 3X/day for 3 days/week during the 3 weeks
  • Ability to travel to three Study Visits
  • Are willing to abstain from consuming grapefruit products during the study
  • Have an iPhone, best with iOS 17 or newer; EXCLUSION:
  • Are currently taking any pharmaceutical drugs for smoking cessation, including: Nicotine patch or nicotine gum, buproprion (Wellbutrin, Zyban), varenicline (Chantix, Champix), other behavioral interventions such as cognitive behavioral therapy for smoking
  • Are currently using cannabis or alcohol for sleep. Are currently taking any pharmaceutical drugs for insomnia, such as eszopiclone (Lunesta), zaleplon (Sonata) or zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) benzodiazepines, or opioids
  • Are currently taking stimulants commonly used for ADHD, such as methylphenidate (Ritalin Concerta, Daytrana) or amphetamines (Adderall, Dexedrine, Vyvanse)
  • Are currently taking anti-seizure drugs, including lamotrigine, pregabalin (Lyrica), or gabapentin (Neurontin, Horizant, or Gralise)
  • Have non-nicotine substance dependence (diagnosed with substance use disorder, including alcohol or cannabis use disorder (current cannabis use is acceptable, and past illicit drug use is acceptable if greater than 2 months prior to testing and does not meet current criteria for substance use disorders (SUDs) according to DSM-5)
  • Have a major neurological disorder such as Parkinson's disease, epilepsy, Alzheimer's disease, multiple sclerosis, or any other serious neurological disorder
  • Have a history of serious psychiatric disorders including bipolar disorder, schizophrenia, or suicidality
  • Had a stroke or head injury which caused loss of consciousness for longer than three minutes in the past 1 year
  • Are pregnant or breastfeeding
  • Have been diagnosed with sleep apnea or other diagnosed sleep disorders such as narcolepsy
  • Have been diagnosed with thyroid problems
  • Have been diagnosed with COPD
  • Have been doing variable shift work in the past 1 month or traveled more than 1 time zone in past month
  • Are currently taking the following medications, supplements, or food: Daridorexant can interact with strong inhibitors of CYP3A4, which should be discussed with The Study Doctor's office (some of these include clarithromycin, diltiazem, erythromycin, itraconzale, ketoconazole, ritonavir, and verapamil)
  • Have a BMI of 33 or higher

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Where in United States

  • Legacy Research InstitutePortland, United StatesContact: Barbara A. Sorg, PhDNot yet recruiting

About the trial

What the trial wants to find out

Tobacco use is the leading cause of preventable death in the U.S., with 480,000 deaths per year and 7.7 million deaths globally. A major clinical symptom associated with abstinence from both licit and illicit drugs is insomnia, which is a clinically verified, major risk factor for relapse. Roughly half of the 40 million smokers in the U.S. attempt to quit annually, with very low rates of success. One major hurdle is poor sleep quality during abstinence. Compounding the problem is that some pharmaceuticals to help reduce smoking can increase insomnia. Poor sleep is recognized as a major impediment to maintaining abstinence from several drugs of abuse, including nicotine. Blockers of orexin have recently been proposed as a promising therapy for smoking cessation. Insomnia has been reported in up to 40% of smokers, and 80% report regular sleep disturbances, which can be amplified during abstinence. A new orexin blocker, daridorexant, was FDA approved within the past two years for the treatment of insomnia, and while it has been tested in healthy individuals with insomnia, it has not been tested in smokers, who suffer from insomnia, particularly during the withdrawal phase when trying to quit. Daridorexant has an improved profile of beneficial effects for those with insomnia, the most notable advantage being its shorter duration of action that promotes daytime alertness, which is problematic for both active smokers and smokers during withdrawal. Poor sleep leads to daytime sleepiness, which often leads to smoking to maintain alertness.

The 2 groups in the trial

  • TreatmentExisting treatment, for comparison

    Treatment: Daridorexant 50 mg

  • No treatmentPlacebo, for comparison

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking During Abstinence
Plain-language title
Daridorexant for sleep problems in smokers who stop smokingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07328594, who can take part
Record updated
9 January 2026